Engineered immune cells aim to tame autoimmune attacks

NCT ID NCT07527936

Terminated Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults and focuses on safety and whether the treatment shows any signs of helping control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BEN301 (a type of immune cell therapy using modified T cells called CAR-Treg cells)
What this could lead to: If it works, this could point toward a new way to control autoimmune diseases by retraining the immune system to stop attacking the body.
What could go wrong: This is a very early, small trial (24 people) that is currently suspended. The therapy is new and may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES(IIM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy myositis disease rheumatoid arthritis Sjogren syndrome systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHIES(IIM) RHEUMATOID ARTHRITIS (RA) SJOGREN'S SYNDROME (SS) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Shanghai Jiaotong University School of Medicine, Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.